You don't need to be signed in to read BMJ Blogs, but you can register here to receive updates about other BMJ products and services via our site.

A gap in the evidence – What is the role of surgery in the patient with severe (secondary) Raynaud’s phenomenon?

21 May, 15 | by BMJ Clinical Evidence

by Ariane Herrick and Lindsay Muir

Herrick

Lindsay_Muir_crop

 

People with Raynaud’s phenomenon secondary to an underlying disease or condition (the best researched one being systemic sclerosis) can progress to irreversible tissue injury with ulceration and/or critical ischaemia and gangrene. Although there has been increasing interest in recent years in identifying new drug therapies for severe Raynaud’s phenomenon with randomised controlled trials (RCTs) of, for example, phosphodiesterase inhibitors and endothelin receptor antagonists, the recent BMJ Clinical Evidence overview identified no RCTs of any of the surgical procedures that  have been advocated for advanced peripheral vascular disease. Specifically, there have been no RCTs of any of the following interventions: botulinum toxin injections, surgical debridement, peripheral (digital, digital plus ulnar and/or radial artery) sympathectomy, cervical/thoracic sympathectomy, arterial reconstruction, or amputation.

The evidence in favour of surgical procedures therefore comes from case series (for example, of botulinum toxin injections and of peripheral sympathectomy) and clinical experience.

The challenge to researchers is how to fill this gap. Given the relatively small numbers of individuals concerned, it is unlikely that RCTs of surgical procedures for severe secondary Raynaud’s phenomenon will be feasible if limited to a single centre, with the possible exception of a study of botulinum toxin injections. Although digital ulceration is a major problem in patients with systemic sclerosis, occurring in up to 50% of cases and causing severe pain, functional disability and disfigurement, systemic sclerosis is itself a rare disease. This, combined with the heterogeneity of the disease process, makes the design and execution of clinical trials highly challenging. The ideal, therefore, is to consider multi-centre studies.  These bring with them a large extra tier of complexity but such challenges can be overcome, as shown in the SWIFFT trial for scaphoid fractures, an exemplar for future studies.

At present, surgery of the fingers and toes – in the absence of a good clinical evidence base – is likely to play an important (but currently inadequately defined) role in the management of people with secondary Raynaud’s phenomenon who are unresponsive to other measures and who have progressed to refractory and/or critical ischaemia. If surgery is to be considered, it is best performed in specialist centres.

Ariane Herrick is Professor of Rheumatology at the University of Manchester and Consultant Rheumatologist at Salford Royal NHS Foundation Trust. She qualified from the University of Aberdeen, trained in general medicine in Glasgow, and in rheumatology in Salford. Her major clinical and research interests are Raynaud’s phenomenon and systemic sclerosis, with a particular emphasis on measurement of microvascular structure and function.

Lindsay Muir is a consultant hand surgeon at Salford Royal Hospital.  He qualified in Glasgow, and trained in hand surgery in Strasbourg, in Wrightington and as the Manchester interface hand fellow.  He has an interest in hand surgery in systemic sclerosis and in finger joint arthroplasty. He has also has a hand trauma practice. He has the privilege of training the interface hand fellows.

By submitting your comment you agree to adhere to these terms and conditions
You can follow any responses to this entry through the RSS 2.0 feed.
BMJ Clinical Evidence Blog homepage

BMJ Clinical Evidence

Clinical Evidence is a database of systematic overviews on the effectiveness of key interventions, together with tools and resources to learn and practise EBM. Visit site



Creative Comms logo

BMJ Clinical Evidence latest news

BMJ Clinical Evidence latest news